Evidence map›Paper›PMID 42768130›Full record

ArticleNature biomedical engineering2026

Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B.

Yesseinia Anglero-Rodriguez, Qiang Xiong, Martino Alfredo Cappelluti, Sarah B Voytek, Glen Acosta, Rayman Choo-Wing, Lenka Hoffman, Arogya Khadka, Jhon A Medina, Caroline Mugambwa and 24 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Yesseinia Anglero-Rodriguez *nChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6674-0595
Qiang Xiong *nChroma Bio, Boston, MA, USA.
Martino Alfredo CappellutiSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-1948-0772
Sarah B VoyteknChroma Bio, Boston, MA, USA.
Glen AcostanChroma Bio, Boston, MA, USA.
Rayman Choo-WingnChroma Bio, Boston, MA, USA.
Lenka HoffmannChroma Bio, Boston, MA, USA.
Arogya KhadkanChroma Bio, Boston, MA, USA.
Jhon A MedinanChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0009-0006-9927-3915
Caroline MugambwanChroma Bio, Boston, MA, USA.
Chloe PantanonChroma Bio, Boston, MA, USA.
Sivan HarelnChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0009-0002-7724-6167
Amber DiPiazzanChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5610-0172
Sameer AbrahamnChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7460-2771
Erica M HildebrandnChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7625-8997
Ricardo N RamireznChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1259-5406
Ava ZhainChroma Bio, Boston, MA, USA.
Xiaoyun GuonChroma Bio, Boston, MA, USA.
Sahar AbubuckernChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5568-5129
Chih-Wei KonChroma Bio, Boston, MA, USA.
Cristiana GiancarlonChroma Bio, Boston, MA, USA.
Bradley NiesnernChroma Bio, Boston, MA, USA.
Matteo ContiSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-3109-4073
Lorena DonniciIstituto Nazionale Genetica Molecolare 'Romeo ed Enrica Invernizzi', Milan, Italy.ORCID http://orcid.org/0000-0002-9153-9102
Pietro SpinellinChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0009-0000-3608-2640
Taesun EomnChroma Bio, Boston, MA, USA.
Mary S MorrisonnChroma Bio, Boston, MA, USA.
Ari E FriedlandnChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4983-1801
Raffaele De FrancescoIstituto Nazionale Genetica Molecolare 'Romeo ed Enrica Invernizzi', Milan, Italy.ORCID http://orcid.org/0000-0001-8754-5123
Angelo LombardoSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0001-8262-042X
Vic E MyernChroma Bio, Boston, MA, USA.
Aron B JaffenChroma Bio, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6220-0476
Melissa BonnernChroma Bio, Boston, MA, USA.
Jennifer L MarlowenChroma Bio, Boston, MA, USA. jmarlowe@nchromabio.com.ORCID http://orcid.org/0009-0002-2258-1953

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approved chronic hepatitis B therapies rarely result in functional cure, as they fail to permanently silence all transcriptionally active hepatitis B virus (HBV) DNA. CRMA-1001 employs an optimized epigenetic silencer that represses viral transcription through targeted deposition of DNA methylation on episomal and integrated HBV DNAs. Here we showed that in HBV mouse models, a single dose of CRMA-1001 produced >3-log

Identifiers

PMID42768130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.